Vectus Biosystems Advances Drug Commercialization

Vectus Biosystems Limited (AU:VBS) has released an update.

Vectus Biosystems Limited has made significant strides in the commercialization of its clinical drug VB0004 and other assets, with expectations of reduced operating costs and a potential R&D refund from the ATO in October 2024. The company has completed Phase Ib human clinical trials for VB0004 with no significant adverse events reported and is progressing on a formal outreach program for licensing and partnerships. Despite the passing of CEO Dr. Karen Duggan, Vectus remains committed to advancing its anti-fibrotic technologies and fulfilling its mission.

For further insights into AU:VBS stock, check out TipRanks’ Stock Analysis page.